Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials
Clicks: 174
ID: 267601
2016
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
174 views
12 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #290 of 1,084 articles by views in clinical infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
In this post-hoc analysis of the phase 3 ION trials evaluating hepatitis C virus therapy with ledipasvir/sofosbuvir ± ribavirin, current opioid substitution the
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (22 words).
Try re-searching for a better abstract.
| Reference Key |
jason2016clinicalefficacy
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Grebely, Jason;Mauss, Stefan;Brown, Ashley;Bronowicki, Jean-Pierre;Puoti, Massimo;Wyles, David;Natha, Macky;Zhu, Yanni;Yang, Junming;Kreter, Bruce;Brainard, Diana M.;Yun, Chohee;Carr, Val;Dore, Gregory J.; |
| Journal | clinical infectious diseases |
| Year | 2016 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.